In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most immunopeptidomic studies either do not consider cysteine modifications18,22,52,54−56 or use cysteinylation as the only cysteine modification allowed in database searches.7,24,27,57”
From Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2021) · cites this paper as [52]
In the citing paper
“The remaining imperfectness in the overlaps implies that the parallel use of different isolation methods can still boost the number of identified peptides strongly”
From Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2021) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Mass spectrometry–based identification of MHC-bound peptides for immunopeptidomics
Purcell, A. W., Ramarathinam, S. H., & Ternette, N. (2019) · Nature Protocols · doi:10.1038/s41596-019-0133-y · Cited by 394
Self-citationZarling, A. L., Ficarro, S. B., White, F. M., Shabanowitz, J., Hunt, D. F., & Engelhard, V. H. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1755 · Cited by 213
Solleder, M., Guillaume, P., Racle, J., Michaux, J., Pak, H.-S., Müller, M., Coukos, G., Bassani-Sternberg, M., & Gfeller, D. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001641 · Cited by 68
Research works printed but not linked: 60
- Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
- Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res., 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
- Alvarez, 2018, Computational tools for the identification and interpretation of sequence motifs in Immunopeptidomes, Proteomics, 12, 1700252, 10.1002/pmic.201700252 · DOI
- Barouch, 1995, HLA-A2 subtypes are functionally distinct in peptide binding and presentation, J. Exp. Med., 182, 1847, 10.1084/jem.182.6.1847 · DOI
- Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol. Cell Proteomics, 14, 658, 10.1074/mcp.M114.042812 · DOI · Paper page
- Bassani-Sternberg, 2017, Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity, PLoS Comput Biol, 13, e1005725, 10.1371/journal.pcbi.1005725 · DOI · Paper page
- Battle, 2013, Molecular characterisation of the monocytic cell line THP-1 demonstrates a discrepancy with the documented HLA type, Int. J. Cancer, 132, 246, 10.1002/ijc.27661 · doi:10.1002/ijc.27661
- Blum, 2013, Pathways Antigen Processing, 31, 443
- Brodsky, 1982, Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants, J. Immunol., 128, 129, 10.4049/jimmunol.128.1.129 · DOI · Paper page
- Caron, 2011, The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation, Mol. Syst. Biol., 7, 533, 10.1038/msb.2011.68 · DOI · Paper page
- Caron, 2015, Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry, Mol. Cell Proteomics, 14, 3105, 10.1074/mcp.O115.052431 · DOI · Paper page
- Casado, 2013, Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors, Genome Biol., 14, R37, 10.1186/gb-2013-14-4-r37 · DOI · Paper page
- Chicz, 1992, Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size, Nature, 358, 764, 10.1038/358764a0 · DOI · Paper page
- Chikata, 2019, Identification of immunodominant HIV-1 epitopes presented by HLA-C*12:02, a protective allele, using an immunopeptidomics approach, J. Virol., 93
- Cobbold, 2013, MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia, Sci. Transl. Med., 5, 10.1126/scitranslmed.3006061 · DOI · Paper page
- Colaert, 2009, Improved visualization of protein consensus sequences by iceLogo, Nat. Methods, 6, 786, 10.1038/nmeth1109-786 · DOI · Paper page
- Cole, 2015, The ultimate mix and match: making sense of HLA alleles and peptide repertoires, Immunol. Cell Biol., 93, 515, 10.1038/icb.2015.40 · DOI
- Croft, 2019, Most viral peptides displayed by class I MHC on infected cells are immunogenic, Proc. Natl. Acad. Sci., 116, 3112, 10.1073/pnas.1815239116 · DOI
- Demmers, 2019, Pre-fractionation extends but also creates a Bias in the detectable HLA class iota ligandome, J. Proteome Res., 18, 1634, 10.1021/acs.jproteome.8b00821 · DOI · Paper page
- Depontieu, 2009, Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 106, 12073, 10.1073/pnas.0903852106 · DOI · Paper page
- Dudek, 2012, Constitutive and inflammatory immunopeptidome of pancreatic β-Cells, Diabetes, 61, 3018, 10.2337/db11-1333 · DOI
- Ebrahimi-Nik, 2019, Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection, JCI Insight, 5
- Escher, 2012, Using iRT, a normalized retention time for more targeted measurement of peptides, Proteomics, 12, 1111, 10.1002/pmic.201100463 · DOI · Paper page
- Falk, 1991, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 290, 10.1038/351290a0 · DOI · Paper page
- Faridi, 2018, In immunopeptidomics we need a sniper instead of a shotgun, Proteomics., 10.1002/pmic.201700464 · DOI · Paper page
- Faure, 2004, Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes, Int. J. Cancer, 108, 863, 10.1002/ijc.11653 · doi:10.1002/ijc.11653
- Frese, 2013, Unambiguous phosphosite localization using electron-transfer/higher-energy collision dissociation (EThcD), J. Proteome Res., 12, 1520, 10.1021/pr301130k · DOI · Paper page
- Freudenmann, 2018, Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry, Immunology, 154, 331, 10.1111/imm.12936 · DOI · Paper page
- Garde, 2019, Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data, Immunogenetics., 10.1007/s00251-019-01122-z · DOI · Paper page
- Gloger, 2016, Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes, Cancer Immunol. Immunother., 65, 1377, 10.1007/s00262-016-1897-3 · DOI · Paper page
- Hoof, 2009, NetMHCpan, a method for MHC class I binding prediction beyond humans, Immunogenetics, 61, 1, 10.1007/s00251-008-0341-z · DOI · Paper page
- Hornbeck, 2012, PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse, Nucleic Acids Res., 40, D261, 10.1093/nar/gkr1122 · DOI · Paper page
- Hulsen, 2008, BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams, BMC Genomics, 9, 488, 10.1186/1471-2164-9-488 · DOI · Paper page
- Hunt, 1992, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261, 10.1126/science.1546328 · DOI · Paper page
- Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147 · DOI · Paper page
- Jurtz, 2017, NetMHCpan-4.0: improved Peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data, J. Immunol., 199, 3360, 10.4049/jimmunol.1700893 · DOI · Paper page
- Kyte, 1982, A simple method for displaying the hydropathic character of a protein, J. Mol. Biol., 157, 105, 10.1016/0022-2836(82)90515-0 · DOI · Paper page
- Loffler, 2019, Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma, Genome Med., 11, 28, 10.1186/s13073-019-0636-8 · DOI · Paper page
- Mason, 1998, A very high level of crossreactivity is an essential feature of the T-cell receptor, Immunol. Today, 19, 395, 10.1016/S0167-5699(98)01299-7 · DOI · Paper page
- Mommen, 2014, Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD), Proc. Natl. Acad. Sci., 111, 4507, 10.1073/pnas.1321458111 · DOI · Paper page
- Narayan, 2019, Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin, PLoS One, 14, 10.1371/journal.pone.0219547 · DOI
- Naylor, 1998, Membrane preconcentration-capillary electrophoresis tandem mass spectrometry (mPC-CE-MS/MS) in the sequence analysis of biologically derived peptides, Talanta, 45, 603, 10.1016/S0039-9140(97)00186-0 · doi:10.1016/s0039-9140(97)00186-0
- Newey, 2019, Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment, J. Immunother. Cancer, 7, 309, 10.1186/s40425-019-0769-8 · DOI
- Olsen, 2017, TANTIGEN: a comprehensive database of tumor T cell antigens, Cancer Immunol. Immunother., 66, 731, 10.1007/s00262-017-1978-y · DOI
- Parham, 1981, Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28, Hum. Immunol., 3, 277, 10.1016/0198-8859(81)90065-3 · DOI · Paper page
- Parker, 1992, Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2, J. Immunol., 149, 3580, 10.4049/jimmunol.149.11.3580 · DOI · Paper page
- Partridge, 2018, Discrimination between human leukocyte antigen class I-Bound and Co-purified HIV-Derived peptides in immunopeptidomics workflows, Front. Immunol., 9
- Perez-Riverol, 2018, The PRIDE database and related tools and resources in 2019: improving support for quantification data, Nucleic Acids Res., 47, D442, 10.1093/nar/gky1106 · DOI · Paper page
- Purcell, 2007, More than one reason to rethink the use of peptides in vaccine design, Nat. Rev. Drug Discov., 6, 404, 10.1038/nrd2224 · DOI · Paper page
- Ramarathinam, 2018, Employing proteomics in the study of antigen presentation: an update, Expert Rev. Proteomics, 15, 637, 10.1080/14789450.2018.1509000 · DOI
- Ramarathinam, 2018, Identification of native and posttranslationally modified HLA-B*57:01-Restricted HIV envelope derived epitopes using immunoproteomics, PROTEOMICS, 18, 10.1002/pmic.201700253 · DOI
- Rammensee, 1995, Chemistry of peptides associated with MHC class I and class II molecules, Curr. Opin. Immunol., 7, 85, 10.1016/0952-7915(95)80033-6 · DOI · Paper page
- Sahay, 2017, Conserved HIV epitopes for an effective HIV vaccine, J. Clin. Cell. Immunol., 8
- Schuster, 2018, A tissue-based draft map of the murine MHC class I immunopeptidome, Sci. Data, 5, 10.1038/sdata.2018.157 · DOI
- Ternette, 2018, Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens, Proteomics, 18
- Tsuchiya, 1980, Establishment and characterization of a human acute monocytic leukemia cell line (THP-1), Int. J. Cancer, 26, 171, 10.1002/ijc.2910260208 · DOI · Paper page
- Woods, 2019, The diversity of the immunogenic components of the melanoma immunopeptidome, bioRxiv
- Zarling, 2006, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 103, 14889, 10.1073/pnas.0604045103 · DOI · Paper page
- Zemmour, 1992, The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon, J. Immunol., 148, 1941, 10.4049/jimmunol.148.6.1941 · doi:10.4049/jimmunol.148.6.1941
- Zhang, 2012, PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification, Mol. Cell Proteomics, 11, 10.1074/mcp.M111.010587 · DOI · Paper page
Cited by
Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00386 · Cited by 63
Metadata
- Authors
- Pandey, K., Mifsud, N. A., Lim Kam Sian, T. C. C., Ayala, R., Ternette, N., Ramarathinam, S. H., & Purcell, A. W.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 123
- Pages
- 7-17
- ISSN
- 0161-5890
- Cited by
- 26
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Cancer Research UK (A21998, 1137739)
- National Health and Medical Research Council (1122099, 1165490)
- Australian Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies. https://app.cochat.ai/papers/10.1016/j.molimm.2020.04.008
- The paper
- Pandey, K., Mifsud, N. A., Lim Kam Sian, T. C. C., Ayala, R., Ternette, N., Ramarathinam, S. H., & Purcell, A. W. (2020). In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies. Molecular Immunology. https://doi.org/10.1016/j.molimm.2020.04.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.